ToolGen Ramps Up CRISPR IP Monetization
Gene-editing company ToolGen announced it is entering a "harvest season" for its global IP monetization and has appointed litigation expert Dave Koo as its new Chief Legal Officer. This strategic shift suggests a more aggressive approach to licensing and enforcement of its CRISPR patents. The move could influence the formation of new patent pools and set precedents for SEP licensing trends in the biotechnology field.
- The global CRISPR patent landscape is dominated by a decade-long dispute between two main groups: the CVC group (University of California, University of Vienna, and Emmanuelle Charpentier) and the Broad Institute (MIT and Harvard). ToolGen represents a third major party in these complex, multi-jurisdictional proceedings. - A key part of ToolGen's new monetization strategy involves active litigation against Vertex Pharmaceuticals over its recently approved CRISPR-based therapy, Casgevy. Lawsuits have been filed in the U.K., the Netherlands, and the U.S., alleging the therapy's manufacturing process infringes on ToolGen's patented CRISPR RNP (ribonucleoprotein) delivery technology. - New Chief Legal Officer Dave Koo brings over 25 years of experience in high-stakes international dispute resolution, including at the top-tier law firm Kim & Chang. His appointment is a clear move to leverage this expertise in ongoing litigation and to negotiate licensing agreements with global companies. - In the U.S., the Patent Trial and Appeal Board (PTAB) is overseeing ongoing interference proceedings to determine which party first invented the use of CRISPR-Cas9 in eukaryotic cells. ToolGen is a key party in these proceedings against both the Broad Institute and the CVC group. - ToolGen holds a portfolio of foundational CRISPR-Cas9 patents in over 10 key jurisdictions, including the U.S., Europe, China, and Japan. The company has previously entered into licensing agreements with major corporations like Monsanto (now Bayer) and Thermo Fisher Scientific. - The fragmented nature of CRISPR patents, with multiple essential patent holders like CVC, Broad, and ToolGen, has led to discussions about forming a patent pool. This situation mirrors the complex licensing environments in telecommunications, where patent pools and standards-essential patent (SEP) frameworks are common solutions to reduce litigation and streamline commercialization.
